SUMO-1 Antibody [SPM571] | 34-179

SUMO-1 Antibody [SPM571] | 34-179 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human,

Homology: N/A

Immunogen: Recombinant human protein was used as the immunogen for this anti-SUMO-1 antibody.

Research Area: Signal Transduction

Tested Application: Flow, IF, WB, IHC

Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Western blot: 0.5-1 ug/ml
Immunohistochemistry (FFPE) : 0.5-1 ug/ml for 30 minutes at RT (1)
Prediluted format: incubate for 30 min at RT (2)
The optimal dilution of the anti-SUMO-1 antibody for each application should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: SPM571

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Sumo Antibody: DAP1, GMP1, PIC1, SMT3, UBL1, OFC10, SENP2, SMT3C, SMT3H3, OK/SW-cl.43, Small ubiquitin-related modifier 1, GAP-modifying protein 1, SUMO-1

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: This mAb is specific to SUMO-1 and shows no cross-reaction with either SUMO2 or SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, SUMO2 and SUMO3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized is precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2, and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1 protein localizes to the nuclear membrane.